Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yibing Yan

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Bioinformatics (Oxford, England)|September 15, 2018
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arraysKevin Y X Wang, Alexander M Menzies, Ines P Silva, et al.
Frontiers in Pharmacology|November 17, 2025
Effect of adjuvant treatment with Xiyanping injection on the prognosis of viral encephalitis in children: a multicenter retrospective studyWen Tian, Yang Chen, Huazhang Liu, et al.
Alzheimer'S Research & Therapy|April 1, 2026
Effects of 40-Hz transcranial alternating current stimulation on cognition and neural markers in Alzheimer's disease: a randomized, sham-controlled trialMiao Fang, Yibing Yan, Wenqian Song, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Bioinformatics (Oxford, England)|September 15, 2018
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arraysKevin Y X Wang, Alexander M Menzies, Ines P Silva, et al.
Frontiers in Pharmacology|November 17, 2025
Effect of adjuvant treatment with Xiyanping injection on the prognosis of viral encephalitis in children: a multicenter retrospective studyWen Tian, Yang Chen, Huazhang Liu, et al.
Alzheimer'S Research & Therapy|April 1, 2026
Effects of 40-Hz transcranial alternating current stimulation on cognition and neural markers in Alzheimer's disease: a randomized, sham-controlled trialMiao Fang, Yibing Yan, Wenqian Song, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 9